Can Taking Statins Cause Gout Flare Ups?

Statins do not raise uric acid levels, and over the long term they tend to lower them, which means they are not a direct cause of gout. But the relationship is more complicated than that reassuring statement suggests. Short-term statin use has been linked to a higher rate of gout flares in population studies, and statins do show up in FDA adverse-event reports for gout. The explanation involves a well-known paradox in gout management and some important differences between individual statin drugs.

What FDA Adverse-Event Reports Actually Show

If you search the FDA’s adverse-event reporting system for drugs associated with gout, lipid-modifying agents (the class that includes statins) rank among the top five drug categories reported alongside new gout diagnoses. A 2025 analysis of that database identified 177 drugs linked to gout reports, with diuretics, blood-pressure medications, cancer drugs, lipid-modifying agents, and immune-modulating drugs appearing most often.¹ That sounds alarming, but adverse-event databases capture reports without proving causation. A drug used by tens of millions of people will accumulate reports for just about every condition, including ones it does not cause. The same analysis found that statins did not rank among the top drug classes for hyperuricemia itself, which is the high uric acid that actually drives gout. That mismatch, appearing in gout reports but not in high-uric-acid reports, hints that something other than a straightforward uric acid increase is going on.

How Statins Affect Uric Acid

Rather than pushing uric acid up, most research shows statins nudge it down, at least modestly. A systematic review and meta-analysis pooling data from multiple randomized trials found that atorvastatin produced a meaningful reduction in serum uric acid, and simvastatin produced a smaller but still statistically significant drop.² A separate meta-analysis broadly agreed on atorvastatin’s effect and also found a significant reduction with pravastatin, though results for rosuvastatin were inconsistent.³

Atorvastatin appears to lower uric acid partly by helping the kidneys excrete more of it. One trial found that atorvastatin increased the urinary fractional excretion of uric acid, meaning more uric acid was being filtered out through urine rather than accumulating in the blood.⁴ A post hoc analysis of the SAGE trial in older patients suggested the drop in uric acid tracked with improvements in kidney filtration: as kidney function got better on atorvastatin, uric acid fell.⁵

So statins, particularly atorvastatin, are not raising uric acid. If anything, they are doing the opposite. This is where the paradox comes in.

Why Lowering Uric Acid Can Trigger a Flare

Anyone who has started allopurinol or another gout medication knows the frustrating reality: the very drugs that lower uric acid can set off gout attacks in the first weeks or months of treatment. Statins can do something similar on a smaller scale. When uric acid drops, urate crystals that have been quietly sitting in joint tissue begin to dissolve. That dissolution exposes crystal surfaces to immune cells, which kick off an inflammatory cascade. The immune system’s alarm pathway, called the NLRP3 inflammasome, gets activated, and inflammatory signaling molecules flood the joint.⁶

The statin-induced drop in uric acid is much smaller than what a dedicated gout drug produces, so most people never notice it. But if you already have a significant urate crystal burden in your joints, even a modest shift may be enough to destabilize those crystals and provoke a flare. This is the most plausible explanation for why statins appear in gout adverse-event reports despite lowering the very substance that causes gout.

Short-Term Risk Versus Long-Term Protection

A large population-based study of patients with high cholesterol found a striking pattern that maps onto this paradox. People who used statins for fewer than three years actually had a higher gout risk compared to those who used statins irregularly, with roughly 70 to 90 percent higher crude rates in the short-term groups. But the picture reversed with longer use: those who stayed on statins for more than three years saw a protective effect, with gout risk dropping by about a quarter compared to irregular users and by half compared to people on other lipid-lowering drugs.⁷

The same study found a dose-dependent pattern. Patients who accumulated more than 720 cumulative defined daily doses saw their gout risk roughly cut in half compared to people taking other lipid drugs. At the lowest cumulative dose range, gout risk was almost double that of irregular users.⁷ The pattern looks a lot like what happens with traditional gout medications: an early window of vulnerability while uric acid shifts, followed by sustained benefit once crystal deposits shrink. The difference is that nobody warns you about this when you start a statin, because the uric acid drop is a side effect rather than the drug’s purpose.

Not All Statins Behave the Same Way

If you have gout and are choosing a statin, the specific drug matters. Atorvastatin consistently produces the largest uric acid reduction. In one head-to-head comparison, atorvastatin lowered uric acid by about 6.5 percent and rosuvastatin by about 3.6 percent, while pitavastatin actually raised uric acid by a non-significant 3.7 percent.⁸ In a year-long randomized trial directly comparing atorvastatin 80 mg with pravastatin 40 mg, atorvastatin lowered uric acid by about 0.5 mg/dL while pravastatin barely moved it.²

That 0.5 mg/dL difference may sound trivial, but for someone hovering near the gout threshold, it can be clinically meaningful. The American Journal of Medicine data on metabolic syndrome and hyperuricemia reinforce that uric acid levels in statin candidates tend to already be elevated, so even a modest nudge in the right direction helps. The flip side is that statins with little uric acid effect, like lovastatin, or ones that might raise it slightly, like pitavastatin, are neutral-to-unhelpful for gout. If your doctor is choosing between statins and you have gout or high uric acid, atorvastatin has the strongest evidence for a favorable uric acid profile.

Statins May Also Dampen Gout Inflammation Directly

Beyond the uric acid effect, there is cell-biology evidence that statins can suppress the specific inflammatory pathway gout exploits. When urate crystals activate immune cells, they trigger the NLRP3 inflammasome, which produces the inflammatory molecules that cause the pain, swelling, and redness of a gout attack. In lab experiments using human immune cells, atorvastatin, simvastatin, and mevastatin all blocked this pathway. They activated a receptor called PPAR-γ, which in turn suppressed the inflammasome and reduced the production of reactive oxygen species that drive inflammation.⁹

Cell-culture results do not always translate to what happens in a person’s joint, but the finding is consistent with the population data showing long-term statin users have fewer gout flares. Over time, statins may be doing double duty: gradually lowering uric acid and tamping down the inflammatory response that urate crystals provoke.

The Colchicine-Statin Interaction You Should Know About

Many people with gout take colchicine to prevent or treat flares, and many of those same people take statins for cholesterol. Both drugs are processed through overlapping liver pathways, and combining them raises the risk of muscle damage. A systematic review identified 38 patients who developed adverse events while taking the combination: about two-thirds developed myopathy (muscle weakness and pain), about a quarter developed rhabdomyolysis (severe muscle breakdown that can damage the kidneys), and a smaller number developed neuromyopathy.¹⁰

An analysis of the FDA adverse-event database confirmed this signal, finding a higher-than-expected proportion of rhabdomyolysis reports among people using colchicine together with atorvastatin or rosuvastatin specifically.¹¹ A separate pharmacovigilance study using the same database reached similar conclusions.¹²

This does not mean you cannot use both drugs. Millions of people do. But it means you should tell every prescriber about both medications, watch for unexplained muscle pain or weakness, and avoid high doses of colchicine if you are on a statin. Kidney impairment increases the risk further because both drugs clear more slowly when the kidneys are not working well. If you develop new muscle symptoms after starting either drug or after a dose increase, get your creatine kinase level checked promptly.

Fenofibrate as a Complementary Option

Fenofibrate, another lipid-lowering drug often used alongside or instead of statins for high triglycerides, has its own uric acid-lowering effect that works through a different mechanism. It blocks a kidney transporter responsible for reabsorbing uric acid back into the blood, which means more uric acid gets excreted in urine.¹³ For someone who needs both cholesterol management and uric acid reduction, combining a statin like atorvastatin with fenofibrate can address both lipids and uric acid from two different angles. This is not a routine recommendation for everyone with gout, but it is worth discussing with a doctor if you have high triglycerides alongside gout, since you get a uric acid benefit from a drug you would already have a reason to take.

Cardiovascular Risk in People With Gout

Gout is strongly associated with cardiovascular disease. High uric acid contributes to endothelial dysfunction, the metabolic conditions that accompany gout (obesity, insulin resistance, high blood pressure) are also cardiovascular risk factors, and the chronic inflammation of poorly controlled gout adds its own burden. This makes statins especially relevant for people with gout, beyond just cholesterol management.

A large general-population cohort study found that gout patients who started statins had a roughly 16 percent lower risk of dying from any cause compared to gout patients who did not start statins. The benefit was even more pronounced among those without pre-existing cardiovascular disease.¹⁴ Observational data like this cannot prove that statins caused the lower mortality — healthier patients may be more likely to start and stay on statins — but the size and consistency of the association reinforce the idea that statins are a net positive for most gout patients, not something to avoid.

Practical Guidance if You Have Gout and Start a Statin

If you already have gout and are prescribed a statin, here is what the evidence suggests you should keep in mind:

Early flares are possible: The first few months on a statin may carry a slightly higher risk of a gout attack, especially if you have a heavy crystal burden. This does not mean the statin is making your gout worse in the long run.
Atorvastatin is the best-studied option: If you have a choice, atorvastatin has the most consistent evidence for lowering uric acid. Pitavastatin and lovastatin appear to have little or no uric acid benefit.
Watch the colchicine combination: If you use colchicine for flare prevention, make sure your prescribers know you are on both. Report any unexplained muscle pain.
Stick with it: The gout-protective effect appears to grow with time. The data suggest meaningful benefit after three or more years of consistent use.
Do not treat statins as gout therapy: The uric acid reduction from statins is a welcome bonus, not a replacement for dedicated urate-lowering therapy like allopurinol or febuxostat if your gout is active or recurrent.

Why Diuretics Deserve More Suspicion Than Statins

When people worry about a medication causing gout, statins often get more scrutiny than they deserve, partly because they are among the most widely prescribed drugs in the world and partly because early flares get noticed. But the same FDA analysis that flagged lipid-modifying agents also ranked diuretics as the single most common drug class in gout reports and among the top five for hyperuricemia.¹ Thiazide and loop diuretics genuinely raise uric acid by reducing how much the kidneys excrete. Many people taking statins for cardiovascular risk are also taking a diuretic for blood pressure. If you start both around the same time and get a gout flare, the diuretic is a far more likely culprit than the statin. A conversation with your doctor about which blood-pressure medication you are on may do more for your gout than worrying about the statin.